Amgen Inc. $AMGN Stake Lifted by Atwood & Palmer Inc.

Atwood & Palmer Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 23.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,840 shares of the medical research company’s stock after purchasing an additional 1,300 shares during the quarter. Atwood & Palmer Inc.’s holdings in Amgen were worth $2,883,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of AMGN. Wellington Altus USA Inc. raised its holdings in shares of Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after buying an additional 34 shares during the period. Tower View Wealth Management LLC boosted its holdings in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Security National Bank of Sioux City Iowa IA purchased a new position in Amgen in the 2nd quarter worth approximately $36,000. Evergreen Advisors LLC acquired a new stake in Amgen in the first quarter valued at approximately $37,000. Finally, Steph & Co. purchased a new stake in shares of Amgen during the third quarter valued at approximately $42,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Truist Financial boosted their target price on shares of Amgen from $362.00 to $380.00 and gave the stock a “hold” rating in a research report on Wednesday. Canaccord Genuity Group raised their price target on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Morgan Stanley cut their price objective on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a report on Wednesday. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Barclays upped their price objective on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $388.29.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a new Phase 3 head-to-head trial for its monthly diabetes injection against semaglutide. Success could strengthen Amgen’s position in the growing GLP-1 market and create a significant future revenue opportunity. Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
• Positive Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing for AI-based genetic testing. The investment could give Amgen access to molecular data that supports more targeted clinical-trial design, though the financial impact is likely limited in the near term. Amgen Backs $30 Million Series A Round
• Positive Sentiment: Recent coverage cited positive investor attention following Amgen’s Sjögren’s syndrome trial update, adding another potential development catalyst to the company’s pipeline. Amgen Announces Sjögren’s Trial Results
• Neutral Sentiment: Amgen’s stock had recently advanced and has substantially outperformed the broader market over the past year. Pre-market indications were broadly stable, suggesting investors are weighing pipeline prospects against valuation and analyst caution. What Would It Take For Amgen Stock to Move Higher?
• Negative Sentiment: Morgan Stanley lowered its price target to $359 from $362 and retained an Equal Weight rating. Truist raised its target to $380 but kept a Hold rating; both targets remain below Amgen’s recent trading level, reinforcing concerns that the stock’s rally may have outpaced near-term fundamentals. Morgan Stanley Adjusts Price Target on Amgen

Amgen Stock Down 1.4%

Shares of AMGN stock traded down $5.64 during mid-day trading on Thursday, reaching $407.44. 2,365,351 shares of the company were exchanged, compared to its average volume of 2,756,801. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The business’s 50 day simple moving average is $411.95 and its 200 day simple moving average is $371.46. The company has a market capitalization of $220.27 billion, a P/E ratio of 25.32, a P/E/G ratio of 2.90 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the prior year, the company posted $6.02 earnings per share. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts predict that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock worth $2,540,926 in the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.